Spruce Street Capital LP 13F holdings
Spruce Street Capital LP reported 30 positions with a total reported value of $509.7M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-13. Top holdings by reported value: KNSA KINIKSA PHARMACEUTICALS INTL (11.5%), RLAY RELAY THERAPEUTICS INC (11.0%), LBRX LB PHARMACEUTICALS INC (8.8%), RLMD RELMADA THERAPEUTICS INC (8.7%), ANRO ALTO NEUROSCIENCE INC (7.0%). Against 2026-03-31 it opened 5 new positions and exited 3. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Spruce Street Capital LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 30 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| KNSA KINIKSA PHARMACEUTICALS INTL | 918,070 | $58.7M | 11.5% |
| RLAY RELAY THERAPEUTICS INC | 2,984,125 | $55.8M | 11.0% |
| LBRX LB PHARMACEUTICALS INC | 1,376,159 | $44.7M | 8.8% |
| RLMD RELMADA THERAPEUTICS INC | 6,391,328 | $44.2M | 8.7% |
| ANRO ALTO NEUROSCIENCE INC | 1,353,047 | $35.7M | 7.0% |
| DNTH DIANTHUS THERAPEUTICS INC | 354,816 | $34.6M | 6.8% |
| ALKS ALKERMES PLC | 543,876 | $28.5M | 5.6% |
| SVRA SAVARA INC | 3,452,576 | $21.3M | 4.2% |
| PCVX VAXCYTE INC | 306,047 | $17.8M | 3.5% |
| ELVN ENLIVEN THERAPEUTICS INC | 329,006 | $16.7M | 3.3% |
| ENTA ENANTA PHARMACEUTICALS INC | 1,088,731 | $15.9M | 3.1% |
| CATX PERSPECTIVE THERAPEUTICS INC | 3,693,931 | $12.6M | 2.5% |
| IFRX INFLARX NV | 5,352,198 | $12.0M | 2.4% |
| SRZN SURROZEN INC | 432,040 | $11.2M | 2.2% |
| ALMS ALUMIS INC | 392,574 | $11.0M | 2.2% |
| IPSC CENTURY THERAPEUTICS INC | 4,059,054 | $9.9M | 2.0% |
| NERV MINERVA NEUROSCIENCES INC | 1,655,500 | $9.2M | 1.8% |
| SABS SAB BIOTHERAPEUTICS INC | 2,198,502 | $8.6M | 1.7% |
| ANTX AN2 THERAPEUTICS INC | 1,661,073 | $8.0M | 1.6% |
| ERAS ERASCA INC | 422,543 | $7.7M | 1.5% |
| IKT INHIBIKASE THERAPEUTICS INC | 3,581,603 | $7.3M | 1.4% |
| RACC RESEARCH ALLIANCE CORP III | 500,000 | $5.3M | 1.0% |
| HLXC HELIX ACQUISITION CORP III | 500,000 | $5.3M | 1.0% |
| ZLAB ZAI LAB LTD | 279,110 | $5.3M | 1.0% |
| ACHV ACHIEVE LIFE SCIENCE INC | 736,637 | $4.8M | 0.9% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 5 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 3 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| CENTESSA PHARMACEUTICALS | 489,849 | $19.5M | 4.7% |
| KALVISTA PHARMACEUTICALS | 897,681 | $18.1M | 4.3% |
| MAZE MAZE THERAPEUTICS INC | 200,000 | $6.0M | 1.4% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ALKS ALKERMES PLC | 317,992 | 543,876 | +71.0% | $28.5M |
| KNSA KINIKSA PHARMACEUTICALS INTL | 761,063 | 918,070 | +20.6% | $58.7M |
| CATX PERSPECTIVE THERAPEUTICS INC | 2,627,107 | 3,693,931 | +40.6% | $12.6M |
| PCVX VAXCYTE INC | 245,709 | 306,047 | +24.6% | $17.8M |
| ENTA ENANTA PHARMACEUTICALS INC | 932,598 | 1,088,731 | +16.7% | $15.9M |
| RLMD RELMADA THERAPEUTICS INC | 6,262,114 | 6,391,328 | +2.1% | $44.2M |
| ANRO ALTO NEUROSCIENCE INC | 1,325,210 | 1,353,047 | +2.1% | $35.7M |
| SVRA SAVARA INC | 3,383,175 | 3,452,576 | +2.1% | $21.3M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| DNTH DIANTHUS THERAPEUTICS INC | 373,274 | 354,816 | -4.9% | $34.6M |
CIK 2050194 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
